PharmGen Science

At a glance

PharmGen Science filed 32 disclosures in the last 12 months, including 5 insider and 3 5% holder. The most recent key filing was on May 12.

Revenue for 2025 was ₩173B, up 1% on 2024. Operating margin was 3.5% against 6.2% a year earlier. Debt was 34% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩91B and operating profit of ₩3.6B.

The 2025 annual report lists 229 employees with an average tenure of 8.1 years and average pay of ₩71.3M, #561 of 1,829 listed companies by average pay. Its 9 directors and auditors were paid ₩260.3M each on average. It paid no cash dividend for 2025. 한의상 and related parties held 19.87% at year end.

From the 2025 annual report

Staff: 229 (149 men, 80 women), of whom 26 on fixed-term contracts. Total pay for the year: ₩16.9B. Directors and auditors: 9, paid ₩2.3B in total.

No cash dividend was paid for 2025.

Largest shareholder

한의상 holds 11.27%; with 5 related parties the group holds 19.87% of common shares at year end (from 12.67% at the start of the year).

Individuals paid ₩500M or more

Auditor: 삼정회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary